Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Long-Term Deferred Tax (2019 - 2023)

Protara Therapeutics' Long-Term Deferred Tax history spans 6 years, with the latest figure at $1.6 million for Q4 2023.

  • Quarterly Long-Term Deferred Tax fell 96.12% to $1.6 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2023, down 96.12% year-over-year, with the annual reading at $1.6 million for FY2023, 96.12% down from the prior year.
  • Long-Term Deferred Tax came in at $1.6 million for Q4 2023, down from $40.5 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $40.5 million in Q4 2022 to a low of $2000.0 in Q4 2019.
  • The 5-year median for Long-Term Deferred Tax is $1.5 million (2021), against an average of $8.8 million.
  • Year-over-year, Long-Term Deferred Tax surged 16000.0% in 2020 and then tumbled 96.12% in 2023.
  • Protara Therapeutics' Long-Term Deferred Tax stood at $2000.0 in 2019, then soared by 16000.0% to $322000.0 in 2020, then soared by 381.06% to $1.5 million in 2021, then skyrocketed by 2512.07% to $40.5 million in 2022, then crashed by 96.12% to $1.6 million in 2023.
  • Per Business Quant, the three most recent readings for TARA's Long-Term Deferred Tax are $1.6 million (Q4 2023), $40.5 million (Q4 2022), and $1.5 million (Q4 2021).